This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
This guideline covers vitamin D use in the context of COVID-19. It is for adults, young people and children in hospitals and community settings. Vitamin D is important for bone and muscle health. It may also have a role in the body's immune response to respiratory viruses.
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes.
This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes.
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic
This guideline covers assessing and managing osteoarthritis in adults. It covers both pharmacological and non-pharmacological treatments. It promotes effective treatment options to control joint pain and improve function in people with osteoarthritis.
This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in
Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in a
NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZenec
This guideline covers pharmacological VTE prophylaxis for patients being treated for COVID-19 pneumonia. It includes patients receiving treatment in hospital or in a community setting such as a ‘hospital at home’ service or COVID-19 ‘virtual ward’. The guideline applies to all patients with COVID-19 pneumonia, including those who have other conditions.
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on swallowable gastric balloon capsules for weight loss in adults. This involves swallowing a capsule containing a balloon that
Evidence-based recommendations on using drug-eluting stents in adults
Evidence-based recommendations on using coronary artery stents in adults
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults
The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.
This guideline sets out an antimicrobial prescribing strategy for human and animal bites (excluding insect bites) in adults, young people and children aged 72 hours and over. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of
Evidence-based recommendations on balloon cryoablation for Barrett’s oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells
Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy
Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy
This quality standard covers assessing and managing heavy menstrual bleeding (menorrhagia), including suspected or confirmed fibroids and adenomyosis. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive
The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
The purpose of this guideline is to ensure the best antibiotic management of suspected or confirmed bacterial pneumonia in adults in hospital during the COVID-19 pandemic. This includes people presenting to hospital with moderate to severe community-acquired pneumonia and people who develop pneumonia while in hospital. It will enable services to make the best use of NHS resources.
The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection.
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.